Bolt Biotherapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 21, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 21, 2024

BOLT$6.43-1.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Stockholders’ Equity

(in thousands, except share amounts)

Additional · Accumulated Other · Total
Common · Paid-In · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance at December 31, 2021	37,399,694	$—	$457,430	$(321)	$(206,990)	$250,119
Issuance of common stock upon vesting of restricted stock units	80,533	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	258,488	—	368	—	—	368
Issuance of common stock upon exercise of stock options	59,187	—	135	—	—	135
Vesting of early exercised options	—	—	4	—	—	4
Stock-based compensation	—	—	9,576	—	—	9,576
Unrealized loss on available-for-sale investments	—	—	—	(598)	—	(598)
Net loss	—	—	—	—	(88,098)	(88,098)
Balance at December 31, 2022	37,797,902	$—	$467,513	$(919)	$(295,088)	$171,506
Issuance of common stock upon vesting of restricted stock units	58,034	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	254,169	1	246	—	—	247
Issuance of common stock upon exercise of stock options	4,501	—	6	—	—	6
Stock-based compensation	—	—	9,223	—	—	9,223
Unrealized gain on available-for-sale investments	—	—	—	956	—	956
Net loss	—	—	—	—	(69,197)	(69,197)
Balance at December 31, 2023	38,114,606	$1	$476,988	$37	$(364,285)	$112,741

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.